Update on augmentation of antidepressant response in resistant depression

  title={Update on augmentation of antidepressant response in resistant depression},
  author={Charles Debattista and Anna Lembke},
  journal={Current Psychiatry Reports},
Most patients in acute depression trials fail to achieve remission with antidepressant monotherapy. Many patients seem to require more than one medication to achieve remission or adequate response. Augmentation strategies are commonly used in clinical practice, but most have been poorly studied. In addition, better-studied strategies, such as the use of lithium and thyroid augmentation, have not been well investigated in combination with newer antidepressants. Various novel strategies are being… Expand
Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials
Clearly larger well designed placebo-controlled studies with longer follow-up accompanied by evaluations of tolerance/dependence are warranted before psychostimulants can be recommended in routine clinical practice for the treatment of MDD. Expand
An evidence-based approach to the management of depression.
This article attempts to answer questions in an evidence-based approach to the management of depression, which focuses on diagnosis, medical management, and complementary treatments. Expand
Modulations of Mammalian Brain Functions by Antidepressant Drugs: Role of Some Phytochemicals as Prospective Antidepressants
Depression in the form of serious mental illness is known to influence overall physiological and cognitive functions of any individual. Existing reports suggest that many brain regions mediate theExpand
The Impact of Residual Symptoms in Major Depression
The incidence of residual symptoms of depression, as well as the risks and consequences of these symptoms, are discussed, and the state of current treatment is reviewed. Expand
Treatments in depression
The treatment of depressive illness does not stop with treatment of acute episodes, and has to be envisaged as a continuous therapeutic intervention, of which the authors are still not able to determine the optimal duration of treatment and the moment that it should be ceased. Expand
Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum
It is postulated that the increase in Golf protein levels result in an increase the proportion of D1 receptors in the high-affinity state and that augmentation of the dopaminergic system exerts the antidepressant effect. Expand
Do thyroid hormones mediate the effects of starvation on mood in adolescent girls with eating disorders?
Low circulating thyroxine concentrations may provide a link between starvation and depression in adolescent girls with ED, according to a logistic regression analysis. Expand
Current perspectives of the roles of the central norepinephrine system in anxiety and depression
Data suggest that the NE interplay with the serotonin system may exert neurobiological normalization of the pathophysiological state of anxious depression, and pharmacological interventions targeting the NE system can result in anxiolytic rather than anxiogenic outcomes when used to treat patients with anxiety and depression. Expand
Treatment-Resistant Depression
The chances for full recovery from major depressive disorder diminish the longer a patient remains depressed—a fact that lends a sense of urgency for appropriate therapy.
Triiodothyronine Is an Indicator of Nutritional Status in Adolescent Girls with Eating Disorders
Serum T3 concentration is an indicator of nutritional status in adolescent girls with eating disorders and could be used to monitor progress throughout nutritional rehabilitation and is sensitive to short-term weight changes. Expand


Augmentation of standard antidepressants with atypical antipsychotic agents for treatment-resistant major depressive disorder.
Dr Papakostas discusses various augmentation strategies, focusing particular on a possible role for the newer atypical antipsychotics, as well as their value as augmenters in TRD awaits further study. Expand
Thyroid hormone treatment of primary unipolar depression: a review.
  • R. Joffe, S. Sokolov
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
  • 2000
There are several limitations to the literature including the fact that most studies have used T3 in tricyclic rather than SSRI failure and most are of relatively short duration, up to 3 wk. Expand
Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors.
Present evidence suggests that a lithium augmentation in depressive patients who do not respond to SSRIs may be an efficacious and generally well tolerated treatment, with a response rate of at least 50% after a period lasting 1 - 2 weeks. Expand
Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants
The data suggest limited usefulness of lithium augmentation for patients refractory to multiple treatments, and more definitive data await the outcome of the NIMH Sequential Treatment Alternatives to Relieve Depression (STAR*D) study. Expand
Psychostimulant augmentation of second generation antidepressants: A case series
The authors attempted to treat Major Depressive Disorder suboptimally responsive to one of the newer (second‐generation) antidepressants by augmentation with a psychostimulant medication, with marked improvement in clinical symptoms of depression. Expand
Dexamethasone augmentation in treatment‐resistant depression
A total of 10 patients who fulfilled DSM‐III‐R criteria for major depression were recruited to the study, each of whom had failed to respond to a 6‐week course of treatment with either sertraline orExpand
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy. Expand
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
This study supports the hypothesis that the combination of a noradrenergic and serotonergic agent is more likely to result in remission than either selective agent alone during a 6-week treatment period. Expand
Aripiprazole augmentation in treatment-resistant depression.
Aripiprazole may be effective as an antidepressant augmentation agent in highly treatment resistant patients who had failed a prior trial of another atypical neuroleptic. Expand
Rapid Reversal of Psychotic Depression Using Mifepristone
Preliminary results suggest that short-term use of GR antagonists may be effective in the treatment of psychotic major depression and that additional study, perhaps using higher doses or more treatment days, seems warranted. Expand